NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

por Khalil, Hilal S., Langdon, Simon P., Kankia, Ibrahim H., Bown, James, Deeni, Yusuf Y.
Publicado 2016

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

por Khalil, Hilal S., Langdon, Simon P., Goltsov, Alexey, Soininen, Tero, Harrison, David J., Bown, James, Deeni, Yusuf Y.
Publicado 2016

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

por Kankia, Ibrahim H., Khalil, Hilal S., Langdon, Simon P., Moult, Peter R., Bown, James L., Deeni, Yusuf Y.
Publicado 2017

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

por Goltsov, Alexey, Deeni, Yusuf, Khalil, Hilal S., Soininen, Tero, Kyriakidis, Stylianos, Hu, Huizhong, Langdon, Simon P., Harrison, David J., Bown, James
Publicado 2014